Corcept Insider Transaction Explained After Shares Tumble 50% in One Day

On Tuesday, William Guyer, the main improvement serviceman of Corcept Therapeutics (NASDAQ:CORT), exercised and instantly sold 20,000 shares done open-market transactions totaling astir $703,656, according to an SEC Form 4 filing.

• What is the derivative discourse of this transaction?
  This lawsuit progressive the workout of 20,000 banal options instantly followed by merchantability of the resulting communal shares connected the unfastened market, with nary indirect vehicles oregon gifting components.

• How did this transaction impact William Guyer's nonstop ownership?
  Direct communal banal holdings declined from 21,235 shares to 1,235 shares, a simplification of 94.18% of his nonstop equity stake; however, helium besides reported holding banal options underlying 250,000 shares aft the transaction.

• What is the remaining equity vulnerability aft this transaction?
  After this sale, Guyer retains 1,235 straight held shares valued astatine astir $44,188.

* 1-year show is calculated utilizing Tuesday arsenic the notation date.

• Corcept Therapeutics generates gross chiefly from Korlym, an FDA-approved therapy for Cushing's syndrome, and is advancing a pipeline of selective cortisol modulators targeting metabolic, oncologic, and neuropsychiatric disorders.

• The institution operates a cause discovery, development, and commercialization model, monetizing proprietary therapies done nonstop income and ongoing objective improvement of caller indications.

• Its superior customers see healthcare providers and specialists treating patients with endocrine and oncology disorders successful the United States.

Corcept Therapeutics is simply a mid-cap biotechnology institution focused connected the improvement and commercialization of therapies for terrible endocrine and oncologic conditions. The institution leverages expertise successful cortisol modulation to code unmet aesculapian needs, supported by a increasing portfolio of proprietary cause candidates. Corcept's established marketplace beingness successful Cushing's syndrome and its advancing objective pipeline supply a instauration for continued maturation and competitory differentiation successful specialized therapeutic markets.